Simulations PlusSLP
SLP
About: Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
Employees: 247
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
93% more call options, than puts
Call options by funds: $393K | Put options by funds: $204K
18% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 50
2.04% more ownership
Funds ownership: 77.03% [Q3] → 79.07% (+2.04%) [Q4]
3% less funds holding
Funds holding: 169 [Q3] → 164 (-5) [Q4]
10% less capital invested
Capital invested by funds: $493M [Q3] → $443M (-$50.3M) [Q4]
13% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 31
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$37
5%
upside
Avg. target
$39
9%
upside
High target
$40
13%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Keybanc Scott Schoenhaus 31% 1-year accuracy 12 / 39 met price target | 13%upside $40 | Overweight Maintained | 16 Apr 2025 |
Keybanc Brett Fishbin 13% 1-year accuracy 2 / 16 met price target | 5%upside $37 | Overweight Maintained | 24 Jan 2025 |
Financial journalist opinion
Based on 10 articles about SLP published over the past 30 days
Neutral
Business Wire
1 day ago
Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced its support of the U.S. Food and Drug Administration's (FDA) recently announced roadmap for reducing animal testing through the use of new approach methodologies (NAMs). Simulations Plus has long provided the i.
Positive
Seeking Alpha
6 days ago
Simulations Plus: Benefiting From FDA Modernization And AI
Simulations Plus, Inc. offers AI-based software tools for drug discovery and optimization, significantly reducing R&D time and costs for pharmaceutical research. SLP's diverse software portfolio, including GastroPlus and ADMET Predictor, and consulting services position it as a comprehensive partner in biotech development. Favorable regulatory changes by the FDA towards AI and non-animal testing methods boost SLP's market potential, despite its current high valuation.
Neutral
Benzinga
1 week ago
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?
The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from traditional animal testing.
Positive
Seeking Alpha
2 weeks ago
Simulations Plus: I See Promising Growth, But I'm Staying Neutral
Simulations Plus, Inc. excels with its AI-driven biosimulation platforms, aiding drug development, but faces challenges with margin erosion and cash flow pressures. Despite strong revenue growth and promising pipeline expansions, operational inefficiencies and rising costs raise concerns about near-term profitability. Management's ability to convert backlog into profitable revenue and stabilize margins is crucial for long-term shareholder value.
Positive
Zacks Investment Research
2 weeks ago
SLP's Q2 Earnings Top, Sales Up Y/Y Despite Industry Headwinds
Simulations Plus' fiscal Q2 2025 performance gains from its strong software solutions and services portfolio amid limited customer funding.
Neutral
Seeking Alpha
2 weeks ago
Simulations Plus, Inc. (SLP) Q2 2025 Earnings Call Transcript
Simulations Plus, Inc. (NASDAQ:SLP ) Q2 2025 Earnings Conference Call April 3, 2025 5:00 PM ET Company Participants Lisa Fortuna - IR, Financial Profiles Shawn O'Connor - CEO Will Frederick - CFO & COO Conference Call Participants David Larsen - BTIG Scott Schoenhaus - KeyBanc Capital Markets Matt Hewitt - Craig-Hallum Christine Rains - William Blair Jeff Garro - Stephens Constantine Davies - Citizen Operator Greetings, and welcome to the Simulations Plus Second Quarter Fiscal 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Positive
Zacks Investment Research
2 weeks ago
Simulations Plus (SLP) Tops Q2 Earnings and Revenue Estimates
Simulations Plus (SLP) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.20 per share a year ago.
Neutral
Business Wire
2 weeks ago
Simulations Plus Reports Second Quarter Fiscal 2025 Financial Results
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its second quarter fiscal 2025, ended February 28, 2025. Second Quarter 2025 Financial Highlights (as compared to second quarter 2024) Total revenue increased 23% to $22.4 million Software.
Positive
Zacks Investment Research
3 weeks ago
Simulations Plus Gears Up for Q2 Earnings: What's in the Offing?
SLP's fiscal Q2 2025 performance is likely to have benefited from continued momentum across its Software and Services segments amid budget constraints.
Positive
Benzinga
3 weeks ago
Top 3 Health Care Stocks That Are Set To Fly This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Charts implemented using Lightweight Charts™